newsfilter
← Latest News
Business Wire·

Realbotix Provides Update on Nasdaq Listing Timeline

XBOTFONCO
  • Realbotix Corp. extended the outside date for its all-stock merger with Onconetix, Inc. to March 31, 2027.
  • The transaction aims to list Realbotix LLC, the robotics & AI subsidiary, on the Nasdaq.
  • Realbotix shareholders will maintain a 75–95% ownership stake in the combined entity without required action or share consolidation.
  • Onconetix advanced $3 million to Realbotix LLC as proof of commitment to complete the deal.
  • The merger amendment removes the minimum net cash closing condition previously required for Onconetix.
  • Realbotix will appoint four of the five directors to the Onconetix board upon transaction close.
  • The deal separates Realbotix LLC's commercial robotics & AI business from the Parent Company's direct-to-consumer operations.
  • The closing capital from Onconetix provides non-dilutive financing to grow the robotics & AI division.
  • Realbotix plans to exhibit Series 1 humanoid robots at the Humanoid Summit in December 2026 & CES 2027 in January 2027.
  • Onconetix is a biotechnology company focused on oncology solutions, including the Proclarix prostate cancer diagnostic test.